FGFR2 Antibody

Code CSB-PA077444
Size US$297
Image
  • Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using FGFR2 antibody.
  • Western blot analysis of extracts from A549 cells, using FGFR2 antibody.
  • Western blot analysis of extracts from HeLa cells (Lane 2) and A549 cells (Lane 3), using FGFR2 antiobdy. The lane on the left is treated with systhesized peptide.
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Full Product Name Rabbit anti-Homo sapiens (Human) FGFR2 Polyclonal antibody
Uniprot No. P21802
Target Names FGFR2
Alternative Names bacteria-expressed kinase antibody; BBDS antibody; BEK antibody; BEK fibroblast growth factor receptor antibody; BFR1 antibody; CD332 antibody; CD332 antigen antibody; CEK3 antibody; CFD1 antibody; Craniofacial dysostosis 1 antibody; ECT1 antibody; FGF receptor antibody; FGFR 2 antibody; FGFR-2 antibody; Fgfr2 antibody; FGFR2_HUMAN antibody; Fibroblast growth factor receptor 2 antibody; Hydroxyaryl protein kinase antibody; Jackson Weiss syndrome antibody; JWS antibody; K SAM antibody; K-sam antibody; Keratinocyte growth factor receptor 2 antibody; Keratinocyte growth factor receptor antibody; KGFR antibody; KSAM antibody; protein tyrosine kinase; receptor like 14 antibody; soluble FGFR4 variant 4 antibody; TK14 antibody; TK25 antibody
Raised in Rabbit
Species Reactivity Human,Mouse
Immunogen Synthesized peptide derived from Human FGFR2.
Immunogen Species Homo sapiens (Human)
Clonality Polyclonal
Purification Method The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
Concentration It differs from different batches. Please contact us to confirm it.
Form Rabbit IgG in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.
Tested Applications ELISA,WB,IHC
Recommended Dilution
Application Recommended Dilution
WB 1:500-1:3000
IHC 1:50-1:100
Protocols ELISA Protocol
Western Blotting(WB) Protocol
Immunohistochemistry (IHC) Protocol
Troubleshooting and FAQs Antibody FAQs
Storage Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Lead Time Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Earn $30 Amazon Card or 20μL/μg CUSABIO Trial Size Antibody. Details of rewards >>

Target Data

Function Tyrosine-protein kinase that acts as cell-surface receptor for fibroblast growth factors and plays an essential role in the regulation of cell proliferation, differentiation, migration and apoptosis, and in the regulation of embryonic development. Required for normal embryonic patterning, trophoblast function, limb bud development, lung morphogenesis, osteogenesis and skin development. Plays an essential role in the regulation of osteoblast differentiation, proliferation and apoptosis, and is required for normal skeleton development. Promotes cell proliferation in keratinocytes and immature osteoblasts, but promotes apoptosis in differentiated osteoblasts. Phosphorylates PLCG1, FRS2 and PAK4. Ligand binding leads to the activation of several signaling cascades. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate. Phosphorylation of FRS2 triggers recruitment of GRB2, GAB1, PIK3R1 and SOS1, and mediates activation of RAS, MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. FGFR2 signaling is down-regulated by ubiquitination, internalization and degradation. Mutations that lead to constitutive kinase activation or impair normal FGFR2 maturation, internalization and degradation lead to aberrant signaling. Over-expressed FGFR2 promotes activation of STAT1.
Gene References into Functions
  1. The results showed no association between two SNPs, rs1219648 and rs2981582, and breast cancer risk, although in a stratified analysis rs2981582 strongly associated with premenopausal and ER-positive breast cancer in Chinese patients. PMID: 30480917
  2. The consequent appearance of the mesenchymal FGFR2c variant in the epithelial context would drive early steps of carcinogenesis. PMID: 29068468
  3. FGFR2 was shown to be markedly overexpressed in gastric cancer tissues and correlated with a high risk of lymph node metastasis and late clinical stage. FGFR2 was negatively associated with TSP4 and FGFR2 activation could downregulate TSP4 expression, which played an important role in the proliferation, invasion and migration of gastric cancer cells. PMID: 30355943
  4. In male breast cancer, smoking habits had a significant effect on overall survival at 10 years. In the same multivariate analysis, we found a significantly higher overall survival in cases with FGFR2 rs2981582 variant in the dominant transmission model A sensitivity analysis with left truncation showed similar results. PMID: 29709729
  5. Results showed that HER2 and FGFR2 are regulated by DDX6 at the post-transcriptional step in gastric cancer. PMID: 29987267
  6. High FGFR2 expression is associated with epithelial ovarian cancer cell proliferation and invasion. PMID: 29970688
  7. There is a wide spectrum of mutations in FGFR2 shown to be causative for Pfeiffer syndrome. Here we report the first Chinese three-generation family with FGFR2 mutation c.514_515delGCinsTT (p.Ala172Phe). PMID: 29782338
  8. It was concluded that miR494 inhibited the cancer initiating cells phenotype and reversed resistance to lapatinib by inhibiting FGFR2 in HER2positive gastric cancer. PMID: 29786108
  9. Patients with very strong FGFR2 mRNA expression showed more homogeneous FGFR2 mRNA expression compared to patients with lower FGFGR2 mRNA expression PMID: 28852882
  10. provide a comprehensive update on FGFR2-related syndromic craniosynostosis PMID: 29230096
  11. The mutations were not present in any of the unaffected family members or unrelated control subjects. These findings expand the mutation spectrum of FGFR2, and are valuable for genetic counseling in addition to prenatal diagnosis in patients with Crouzon syndrome. PMID: 28901406
  12. Fibroblast growth factor receptor 2 (FGFR2) splice site variants were identified in eight patients with Crouzon or Pfeiffer syndrome. PMID: 26841243
  13. Data suggest that the SOX9 transcription factor (SOX9)-fibroblast growth factor receptor 2 (FGFR2b) feed-forward loop has a lineage dependency role in pancreatic ductal adenocarcinoma (PDAC). PMID: 28796141
  14. this study reports for the first time the p.W290G mutation in patients with PS. Based on clinical features, genetic, and computational analysis and genotype-phenotype association studies PMID: 28815901
  15. Studies indicate that switching from fibroblast growth factor receptor 2 (FDFR-2) IIIb to IIIc variants correlates with the aggressiveness of the cancers via epithelial-mesenchymal transition [Review]. PMID: 28930565
  16. These results unveil the complexity of ER regulation by FGFR2-mediated signaling likely to be associated with BCa resistance to endocrine therapy. PMID: 28869838
  17. Study report that 5-10% of epidermal nevi harbor embryonic postzygotic FGFR2 activating mutations. PMID: 27103312
  18. this study identified an FGFR2 in two Chinese patients with syndromic craniosynostosis. The finding expands the reported mutation spectrum of FGFR2, and is of great value for genetic counseling and prenatal diagnosis in families with syndromic craniosynostosis. PMID: 28849010
  19. Through a stratification analysis, 5q11.2/MAP3K1 (rs16886034, rs16886364, rs16886397, rs1017226, rs16886448) and 7q32.3/LINC-PINT (rs4593472) were associated with Luminal A, and 10q26.1/FGFR2 (rs35054928) was associated with Luminal B. PMID: 28408616
  20. SNORD126 activates the PI3K-AKT pathway by upregulation of FGFR2. PMID: 27913571
  21. This study reveals a direct binding event and characterizes the role of TRPA1 ankyrin repeats in regulating FGFR2-driven oncogenic process; a mechanism that is hindered by miRNA-142-3p PMID: 29038531
  22. Although FGFR2 amplification is associated with poorer OS, it does not appear to be an independent prognostic predictor in patients with advanced gastric cancer treated with palliative fluoropyrimidine and platinum chemotherapy. PMID: 27802183
  23. This meta-analysis of case-control studies provides strong evidence that FGFR2 (rs2981582, rs2420946 and rs2981578) polymorphisms were significantly associated with the BC risk. PMID: 27966449
  24. we further refine the influence of variants in the FGFR2 locus with respect to molecular characteristics of breast tumors, in that they are more strongly associated with estrogen receptor status among cancers without amplification of the HER2 gene. PMID: 27764800
  25. Suggest FGFR2 as a novel acute myeloid leukemia susceptibility gene with a haplotype TT (rs7090018 and rs2912759) showing significant association with AML. PMID: 27903959
  26. Result demonstrated that FGFR2 high-expression was significantly associated with unfavorable prognosis of gastric adenocarcinoma and that SPRY2 could inhibit FGFR2-induced ERK phosphorylation and suppress FGFR2-elicited gastric cancer cell proliferation and invasion. PMID: 28002800
  27. By means of structural (X-ray and NMR) and functional characterization of pathogenic gain-of-function mutations affecting the FGF receptor (FGFR) tyrosine kinase domain, the authors elucidated a long-distance allosteric network composed of four interconnected sites termed the 'molecular brake', 'DFG latch', 'A-loop plug', and 'alphaC tether'. The first three sites repress the kinase from adopting an active conformation... PMID: 28166054
  28. Besides, we found miR-628-5p targeted at and down-regulated the expression of fibroblast growth factor receptor 2 (FGFR2). FGFR2 expressed higher in ovarian cancer tissues and was correlated with worse prognosis. Our findings indicated that miR-628-5pplays an important role in ovarian cancer stem cell driven tumorigenesis. PMID: 29229394
  29. Mandibular growth in children with FGFR2 mutations is not normal with impairments found in forward sagittal growth and skull base widening PMID: 28468153
  30. Inhibiting Fgf-R partly reversed alphavbeta3 integrin activity in Mll-Ell+ progenitor cells. PMID: 27340869
  31. In gastric cancer, FGFR2 protein overexpression predicts gene amplification and poor survival. PMID: 27230412
  32. Her2, cMet and FGFR2 statuses were profiled in gastric cancer (GC) patients and the -derived tumor xenograft(PDX) models. PMID: 28292264
  33. We demonstrate that the bent bone dysplasia syndrome mutations in FGFR2 p.M391R and p.Y381D augment the ability of FGFR2 to epigenetically activate rDNA. Mutations p.M391R and p.Y381D activate the p53 nucleolar stress response pathway and alter FGFR2-mediated activation of ribosome biogenesis. PMID: 28595297
  34. Polyclonal secondary FGFR2 mutations represent an important clinical resistance mechanism to protein kinase inhibitors in patients with FGFR2 fusion-positive cholangiocarcinoma. PMID: 28034880
  35. CD44 and FGFR2 maintain stemness in gastric cancer by differentially regulating c-Myc transcription. PMID: 27107424
  36. a novel identical postzygotic activating FGFR2 mutation in two unrelated fetuses with papillomatous pedunculated sebaceous naevus. PMID: 27095246
  37. Findings suggest fibroblast growth factor receptor 2 (FGFR2) as a therapeutic target for esophagogastric junction (EGJ) adenocarcinoma. PMID: 26933914
  38. Description of these patients expands the prenatal and postnatal findings of Bent Bone Dysplasia-FGFR2 type and adds to the phenotypic spectrum among all FGFR2 disorders. PMID: 27240702
  39. Our results imply that the same FGFR2 mutations result in diverse phenotypes, and that genetic studies are recommended not only for obviously affected individuals but also for family members with apparently normal phenotype or non-specific subtle abnormal phenotype. PMID: 27683237
  40. Liensinine inhibits FGFR2 activity. PMID: 28132898
  41. FGFR2-ACSL5 fusion is associated with resistance to LY2874455 in FGFR2-amplified gastric cancer . PMID: 28122360
  42. FGFR2 mutation is associated with endometrial carcinoma progression and abdominopelvic metastasis. PMID: 27348297
  43. FGFR inhibitors, particularly BGJ398, are therapeutic options for cholangiocarcinoma patients harboring FGFR2-CCDC6 fusions. PMID: 27216979
  44. High FGFR2 expression is associated with Gastric Cancers. PMID: 27197184
  45. Two novel FGFR 2 gene missense mutations in Chinese patients with Crouzon syndrome were identified. PMID: 27430617
  46. Incidence of progression (progressed, recurred or died from disease) of endometrioid endometrial cancer was significantly more prevalent (32/125, 26%) among patients with FGFR2 mutation versus wild type (120/848, 14%; p<0.001, Chi-square test). PMID: 28314589
  47. We show that this stabilizes the tyrosine and primes it for the catalytic phosphotransfer, and it may lower the activation barrier of the phosphotransfer reaction. Our work demonstrates the value of including dynamic information gleaned from computer simulation in deciphering RTK regulatory function. PMID: 28151998
  48. We show that the decrease in PI(4,5)P2 level under non-stimulated conditions inhibits PTEN activity leading to the aberrant activation of the oncoprotein Akt. As well as defining a novel mechanism of Akt phosphorylation with important therapeutic consequences, we also demonstrate that differential expression levels of FGFR2, Plc11 and Grb2 correlate with patient survival PMID: 26212011
  49. High FGFR2 expression was significantly associated with the depth of invasion, lymph-node metastasis, pathological stage, and distant metastasis or recurrent disease in gastric cancer. PMID: 28056982
  50. fibroblast growth factor receptor 2 overexpression is correlated with decreased survival in most solid tumors, suggesting that the expression status of fibroblast growth factor receptor 2 is a valuable prognostic biomarker and a novel therapeutic target in human solid tumors. PMID: 28618942

Show More

Hide All

Involvement in disease Crouzon syndrome (CS); Jackson-Weiss syndrome (JWS); Apert syndrome (APRS); Pfeiffer syndrome (PS); Beare-Stevenson cutis gyrata syndrome (BSTVS); Familial scaphocephaly syndrome (FSPC); Lacrimo-auriculo-dento-digital syndrome (LADDS); Antley-Bixler syndrome, without genital anomalies or disordered steroidogenesis (ABS2); Bent bone dysplasia syndrome (BBDS); Saethre-Chotzen syndrome (SCS)
Subcellular Location Cell membrane, Single-pass type I membrane protein, Golgi apparatus, Cytoplasmic vesicle, Note=Detected on osteoblast plasma membrane lipid rafts, After ligand binding, the activated receptor is rapidly internalized and degraded, SUBCELLULAR LOCATION: Isoform 1: Cell membrane, Single-pass type I membrane protein, Note=After ligand binding, the activated receptor is rapidly internalized and degraded, SUBCELLULAR LOCATION: Isoform 3: Cell membrane, Single-pass type I membrane protein
Protein Families Protein kinase superfamily, Tyr protein kinase family, Fibroblast growth factor receptor subfamily
Database Links

HGNC: 3689

OMIM: 101200

KEGG: hsa:2263

STRING: 9606.ENSP00000410294

UniGene: Hs.533683

Newsletters

Get all the latest information on Events, Sales and Offers. Sign up for newsletter today.

© 2007-2020 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1